Visual Performance And Proms Of A Novel Presbyopia-Correcting Iol With Wavefront-Shaping Technology Implanted In Patients With Dry Eye In A Real-World Registry Study

Purpose (229/750 characters): To investigate the real-world visual outcomes in subjects bilaterally implanted with AcrySof IQ Vivity presbyopia-correcting IOLs (models DFT015 and DFTX15-Toric). Here, we report outcomes for the subgroup with previous dry eye

Multicenter, ambispective registry study conducted in Europe, the UK, Australia and New Zealand evaluating the performance of bilaterally implanted AcrySof IQ Vivity and AcrySof IQ Vivity Toric IOL in a real world setting through routine clinical practice.

After a minimum of 3 months follow-up, binocular uncorrected and corrected visual acuities at distance (UCDVA, BCDVA), intermediate (UCIVA, DCIVA; 66 cm) and near (UCNVA, DCNVA; 40 cm) were measured. Spectacle independence, patient satisfaction and visual disturbances were also evaluated.

To date, 66 patients with dry eye have been implanted bilaterally with DFT015 or DFTX15-Toric IOLs. At the study entry visit (~3 months), binocular mean logMAR (standard deviation) UCDVA was 0.026 (0.118), UCIVA 0.088 (0.132) and UCNVA 0.222 (0.150). Similarly, binocular mean BCDVA was -0.022 (0.082), DCIVA 0.092 (0.129) and DCNVA 0.260 (0.133). The majority of subjects never or rarely needed to wear spectacles for distance or intermediate tasks (≥84.6% and ≥69.2% in bright and dim conditions, respectively). High levels of satisfaction were observed, with 78.4% of subjects reporting that they were satisfied with their sight. In addition, no halos, glare or starbursts were reported by 90.8%, 93.8% and 92.3% of subjects, respectively

In this study, subjects with dry eye bilaterally implanted with DFT015 or DFTX15-Toric IOLs achieved good distance, intermediate and functional near vision. Subjects in this subgroup also reported good levels of spectacle independence, high levels of satisfaction with their vision, and low levels of visual disturbances.